For decades, academia and the biopharma industry have been delivering scientific innovation and, consequently, new therapies to millions of patients around the world. Despite significant scientific progress, tremendous unmet medical needs persist, particularly in autoimmune diseases. More than 24 million people in the United States and approximately 4 percent of the world’s population are living with these chronic, debilitating conditions. For many autoimmune diseases, including Rheumatoid Arthritis, Inflammatory Bowel Disease and Type 1 Diabetes, the treatments are inadequate and not curative, leaving patients and their support networks to suffer from these often-devastating diseases. Thus, it’s not hard to imagine the potential impact on patients’ lives if we were able to devise a new class of medicines that would halt (or even reverse) progression of these conditions.
At Sonoma Bio, we believe we are at the forefront of a new pillar of medicine, living cell therapies that can be engineered to be specific, safe and curative.